Logo image of KALA

KALA BIO INC (KALA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KALA - US4831192020 - Common Stock

0.6752 USD
-0.02 (-2.82%)
Last: 12/12/2025, 8:00:02 PM
0.6588 USD
-0.02 (-2.43%)
Pre-Market: 12/15/2025, 7:27:24 AM
Fundamental Rating

1

Taking everything into account, KALA scores 1 out of 10 in our fundamental rating. KALA was compared to 529 industry peers in the Biotechnology industry. KALA has a bad profitability rating. Also its financial health evaluation is rather negative. KALA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KALA has reported negative net income.
In the past year KALA has reported a negative cash flow from operations.
KALA had negative earnings in each of the past 5 years.
KALA had a negative operating cash flow in each of the past 5 years.
KALA Yearly Net Income VS EBIT VS OCF VS FCFKALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -74.28%, KALA is doing worse than 64.08% of the companies in the same industry.
KALA's Return On Equity of -627.91% is on the low side compared to the rest of the industry. KALA is outperformed by 78.26% of its industry peers.
Industry RankSector Rank
ROA -74.28%
ROE -627.91%
ROIC N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
KALA Yearly ROA, ROE, ROICKALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

KALA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALA Yearly Profit, Operating, Gross MarginsKALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, KALA has more shares outstanding
Compared to 5 years ago, KALA has more shares outstanding
Compared to 1 year ago, KALA has an improved debt to assets ratio.
KALA Yearly Shares OutstandingKALA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
KALA Yearly Total Debt VS Total AssetsKALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

KALA has an Altman-Z score of -21.52. This is a bad value and indicates that KALA is not financially healthy and even has some risk of bankruptcy.
KALA has a worse Altman-Z score (-21.52) than 85.82% of its industry peers.
KALA has a Debt/Equity ratio of 2.65. This is a high value indicating a heavy dependency on external financing.
KALA has a worse Debt to Equity ratio (2.65) than 81.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Altman-Z -21.52
ROIC/WACCN/A
WACCN/A
KALA Yearly LT Debt VS Equity VS FCFKALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 1.99 indicates that KALA should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.99, KALA is doing worse than 77.32% of the companies in the same industry.
KALA has a Quick Ratio of 1.99. This is a normal value and indicates that KALA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.99, KALA is doing worse than 75.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
KALA Yearly Current Assets VS Current LiabilitesKALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

KALA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.09%, which is quite impressive.
EPS 1Y (TTM)54.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.21% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.59%
EPS Next 2Y38.5%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALA Yearly Revenue VS EstimatesKALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2021 2022 2031 2032 50M 100M 150M
KALA Yearly EPS VS EstimatesKALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

KALA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KALA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALA Price Earnings VS Forward Price EarningsKALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALA Per share dataKALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as KALA's earnings are expected to grow with 25.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.5%
EPS Next 3Y25.21%

More info and screens

0

5. Dividend

5.1 Amount

KALA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KALA BIO INC

NASDAQ:KALA (12/12/2025, 8:00:02 PM)

Premarket: 0.6588 -0.02 (-2.43%)

0.6752

-0.02 (-2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-19 2025-11-19/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners17.29%
Inst Owner Change-43.72%
Ins Owners2.03%
Ins Owner Change-6.56%
Market Cap5.54M
Revenue(TTM)N/A
Net Income(TTM)-35.84M
Analysts45.71
Price Target1.53 (126.6%)
Short Float %5.78%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.62%
Min EPS beat(2)1.58%
Max EPS beat(2)41.67%
EPS beat(4)4
Avg EPS beat(4)25.08%
Min EPS beat(4)1.58%
Max EPS beat(4)41.67%
EPS beat(8)7
Avg EPS beat(8)15.48%
EPS beat(12)7
Avg EPS beat(12)-2.76%
EPS beat(16)9
Avg EPS beat(16)-6.64%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.28%
ROE -627.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -21.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)113.01%
Cap/Depr(5y)128.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.44%
EPS Next Y49.59%
EPS Next 2Y38.5%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.7%
OCF growth 3YN/A
OCF growth 5YN/A

KALA BIO INC / KALA FAQ

What is the fundamental rating for KALA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KALA.


Can you provide the valuation status for KALA BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to KALA BIO INC (KALA). This can be considered as Overvalued.


How profitable is KALA BIO INC (KALA) stock?

KALA BIO INC (KALA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for KALA BIO INC?

The Earnings per Share (EPS) of KALA BIO INC (KALA) is expected to grow by 49.59% in the next year.